Results 41 to 50 of about 3,046 (215)

Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Milind Y. Desai, Andrew Gaballa, Yuichiro Okushi, Mohammed Abusafia, Shada Jadam, Katy Rutkowski, Susan Ospina, Sanaa Sultana, Maran Thamilarasan, Craig Asher, Zoran B. Popovic, Bo Xu   +11 more
doaj   +2 more sources

Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis [PDF]

BMC Cardiovascular Disorders
Background Mavacamten is a novel selective cardiac myosin inhibitor indicated for patients with obstructive hypertrophic cardiomyopathy (oHCM). Given its negative inotropic properties, which theoretically reduce myocardial contractility and affect left ...
Lingqing Ding, Xinhang Liao, Yongkuan Yang, Congqin Chen, Jie Xiao   +4 more
doaj   +2 more sources

Mavacamten maintenance dose determination: insights into individualised therapy for hypertrophic cardiomyopathy

Open Heart
Aims Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction.
S. Scholtz, C. Coppée, K. Mohemed, M. Potratz, V. Sequeira, Volker Rudolph, W. Scholtz, J. Reil   +7 more
semanticscholar   +2 more sources

Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction [PDF]

Frontiers in Medicine
BackgroundMavacamten targets cardiac myosin ATPase, reducing the formation of actin-myosin cross-bridges, which alleviates excessive myocardial contraction and improves diastolic function.
Lijia Yang, Hongyan Dai, Yuanyuan Rong
doaj   +2 more sources

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions

Drug Design, Development and Therapy, 2023
Tiffany Dong,* Ben Alencherry,* Susan Ospina, Milind Y Desai Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA*These authors contributed equally to this workCorrespondence: Milind ...
Tiffany Dong, Ben Alencherry, Milind Y Desai   +2 more
exaly   +2 more sources

Mavacamten in Right Ventricular Outflow Tract Obstruction

JACC: Case Reports
Right ventricular outflow tract (RVOT) obstruction is a rare complication of ventricular hypertrophy in patients with hypertrophic cardiomyopathy (HCM). This study presents an unusual case of a patient with HCM with severe RVOT obstruction that was relieved successfully through the use of mavacamten.
Jasmine K. Malhi, Richard T. Carrick, Chloe Duvall, Faisal Rahman, Matthew W. Martinez, Jose Madrazo, Lili A. Barouch   +6 more
openaire   +4 more sources

Incidence and Outcomes of Atrial Fibrillation and Systolic Dysfunction in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: A Multicenter Study

medRxiv
Key points Question: What are the real-world burden and consequences of atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy treated with commercial mavacamten?
O. Nguyen, J. Wiedrick, D. Massera, Elizabeth Adlestein, Sumar Frejat, M. Castrichini, S. Alsidawi, J. Giudicessi, J. Geske, Richard T Carrick, Jose Madrazo, Nicole Dellise, Mark A. Zenker, Thomas A. Boyle, Nosheen Reza, A. T. Owens, David S. Frankel, Prabhjot Hundal, J. Tajik, Patrycja Z. Galazka, Myra Lewontin, Michael Ayers, Timothy C. Wong, M. Flanagan, S. Mitter, A. Kanwal, O. Bilen, Sarah Baghdadi, Hirak Shah, Jared A. Kvapil, Paola Roldan, L. Berenbom, Jill Jesurum, Denise Tootill, Alice Siqueira-Benzow, Mariko Harper, D. Saleh, L. Choudhury, Isabela Valenta, M. Lang, Dermot M. Phelan, Dmitry Prizand, Neal K. Lakdawala, Carolyn Ho, L. Liang, S. Weiner, S. Ravi, A. Abuzaid, Mohammed Makkiya, Jeremy S. Markowitz, M. Sherrid, A. Masri   +51 more
semanticscholar   +2 more sources

ECG markers of left ventricular hypertrophy indicate response to mavacamten in hypertrophic obstructive cardiomyopathy

Open Heart
Background Mavacamten has revolutionised the treatment of hypertrophic obstructive cardiomyopathy (HOCM) but requires frequent follow-up. Routine ECG may offer an accessible tool to indicate response to therapy.
Tienush Rassaf, Florian Buehning, Tobias Lerchner, Julia Vogel, Lea Kolk, Lukas Vogel, Katharina Seuthe, Peter Ferdinandy, Amir Abbas Mahabadi, Lars Michel   +9 more
doaj   +2 more sources

Efficacy and safety of mavacamten in non-obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis of randomized trials [PDF]

International Journal of Cardiology: Heart & Vasculature
Background: Non-obstructive hypertrophic cardiomyopathy (nHCM) remains a therapeutic challenge, with limited pharmacological options beyond symptomatic management.
Muhammad Abdullah, Husna Irfan Thalib, Mustafa Bin Tahir, Noman Khalid, Ahmad Mushtaq, Muhammad Adil Afzal, Michael D Moore, Nagaraja Sharma, Salman Muddassir, Michael Parker Ayers, Mazen Albaghdadi, Wilbert S. Aronow   +11 more
doaj   +2 more sources

Mavacamten maintenance dose determination

\(\bf Aims\) Mavacamten, the first approved myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy (oHCM), addresses hypercontractility and left ventricular outflow tract (LVOT) obstruction. This study evaluates real-world experience with mavacamten, focusing on maintenance dose determination to optimise individual therapy and enhance
Scholtz, Smita (PD Dr. med.), Coppée, Cédric (Dr. med.), Mohemed, Kawa (Dr. med.), Potratz, Max (Dr. med.), Sequeira, Vasco (Dr. rer. nat.), Rudolph, Volker (PD Dr. med.), Scholtz, Werner (Dr. med.), Reil, Jan-Christian (Dr. med.)   +7 more
openaire   +2 more sources